DrugDev has added technology features to its platform for clinical trial optimization with its new site activation module, which can reduce startup time from months to weeks. DrugDev’s site activation technology, now available to customers directly as a SaaS solution in addition to traditional outsourcing, enables companies to enhance efficiency, improve site relationships and reduce the time spent on startup activities by at least 20%.

DrugDev technology supports collaboration between sponsors, CROs and sites by providing complete transparency into the real-time status for clinical trial agreement (CTA) negotiations, budget development and essential regulatory document collection. The system features an intuitive interface with single sign-in that guides users to complete outstanding actions, visual real-time progress dashboard reports, and unification throughout the DrugDev platform for learning management, site engagement and study workflow optimization.

Customers receive additional value by integrating the DrugDev Golden Number, a universal identifier that powers the revolutionary TransCelerate Investigator Registry and the Investigator Databank collaborations, throughout the site activation process. The Golden Number can be implemented for site activation as well as in other clinical systems (e.g. site selection, DrugDev Payments, EDC, CTMS) to create master profiles for sites and investigators around the world.

CTAs are further simplified by leveraging prior existing contract language (where available) to streamline negotiations and ensure consistency of terms, while the ease of collecting and maintaining regulatory documents delivers a painless process that eliminates site frustration and removes a significant barrier to trial participation.

Ibraheem Mahmood, president and CEO of DrugDev, said, “We’ve been working with customers for years to transform what is otherwise a very frustrating and time-consuming process, which often generates friction with sites, into an efficient and transparent collaboration that wraps up in a few weeks rather than dragging on for several months. To be honest, I feel a bit guilty for having kept this technology to ourselves for so long, so I’m relieved and excited we are finally making it available directly to sponsors and CROs. As would be expected, the module is integrated into our award-winning platform and leverages the DrugDev Golden Number to ensure overall clinical operations success for our valued customers.”

Melissa Easy, DrugDev founder and president of Site Startup, said, “The best part of delivering our activation technology as a SaaS solution is the flexibility and choice it provides. Every trial is different, so sponsors and CROs who want to streamline the startup process may elect to outsource responsibility to our expert team, use our technology themselves, have a CRO partner use it, or engage in a hybrid that combines the models. The whole point is finding the right site, getting them activated, and setting them up for success as quickly as possible. By combining the DrugDev platform, the DrugDev Golden Number and our global network of investigators, customers will identify ideal investigators, execute CTAs, collect essential site regulatory documents, and activate trials faster than anyone thought possible.”